The king is dead (warfarin): direct thrombin and factor Xa inhibitors: the next Diadochian War?


Journal Article

Atrial fibrillation is an important risk factor for stroke. New drugs for oral anticoagulation that do not exhibit the limitations of vitamin K antagonists like warfarin are under investigation. These include direct factor Xa inhibitors and direct thrombin-inhibitors. Recent studies provide promising results for apixaban, dabigatran, and rivaroxaban, including higher efficacy and significantly lower incidences of intracranial bleeds compared with warfarin. The new oral anticoagulants substances show similar results in secondary as in primary stroke prevention in patients with AF and will on the long run replace warfarin.

Full Text

Duke Authors

Cited Authors

  • Diener, H-C; Eikelboom, J; Granger, CB; Hacke, W

Published Date

  • February 2012

Published In

Volume / Issue

  • 7 / 2

Start / End Page

  • 139 - 141

PubMed ID

  • 22264366

Pubmed Central ID

  • 22264366

Electronic International Standard Serial Number (EISSN)

  • 1747-4949

Digital Object Identifier (DOI)

  • 10.1111/j.1747-4949.2011.00739.x


  • eng

Conference Location

  • United States